药品批准更新
Pharmaceutical Approval Update.
作者信息
Choy Mary
出版信息
P T. 2018 Apr;43(4):205-227.
Abstract
Netarsudil ophthalmic solution (Rhopressa) for the reduction of elevated intraocular pressure; ertugliflozin (Steglatro) for adults with type-2 diabetes; and lutetium lu 177 dotatate (Lutathera) for certain gastroenteropancreatic neuroendocrine tumors.
摘要
用于降低眼压的奈他地尔眼药水（Rhopressa）；用于2型糖尿病成人患者的艾托格列净（Steglatro）；以及用于某些胃肠胰神经内分泌肿瘤的镥Lu 177 奥曲肽（Lutathera）。
相似文献
1
Pharmaceutical Approval Update.药品批准更新
P T. 2018 Apr;43(4):205-227.
2
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.镥 Lu 177 奥曲肽（Lutathera）用于胃肠胰神经内分泌肿瘤
Med Lett Drugs Ther. 2018 Sep 10;60(1555):e152-e153.
3
Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.靶向治疗：用于治疗胃肠胰神经内分泌肿瘤的新型放射性标记生长抑素类似物
Clin J Oncol Nurs. 2018 Oct 1;22(5):565-568. doi: 10.1188/18.CJON.565-568.
4
Netarsudil Ophthalmic Solution 0.02%: First Global Approval.奈他舒地尔滴眼液 0.02%：全球首次获批。
Drugs. 2018 Mar;78(3):389-396. doi: 10.1007/s40265-018-0877-7.
5
Lutetium Lu 177 Dotatate Approved by FDA.镥 Lu 177 奥曲肽获美国食品药品监督管理局批准。
Cancer Discov. 2018 Apr;8(4):OF2. doi: 10.1158/2159-8290.CD-NB2018-021. Epub 2018 Feb 27.
6
Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.0.02%奈他地尔眼药水用于治疗开角型青光眼或高眼压症患者。
Drugs Today (Barc). 2018 Aug;54(8):467-478. doi: 10.1358/dot.2018.54.8.2849627.
7
A Care Process Model to Deliver Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.一种为神经内分泌肿瘤患者提供镥-奥曲肽肽受体放射性核素治疗的护理流程模型。
Front Oncol. 2019 Jan 9;8:663. doi: 10.3389/fonc.2018.00663. eCollection 2018.
8
Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.《[Lu-DOTA,Tyr]octreotate 治疗胃肠胰和支气管神经内分泌肿瘤患者的长期疗效、生存和安全性》。
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.
9
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
10
Evaluation of the Interaction of Amino Acid Infusion on Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.评价氨基酸输注对胃肠胰神经内分泌肿瘤患者 Lu-Dotatate 药代动力学的影响。
Clin Pharmacokinet. 2019 Feb;58(2):213-222. doi: 10.1007/s40262-018-0674-1.
引用本文的文献
1
Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center.他氟前列素辅助治疗的实用评估：来自一家三级护理中心的回顾性图表分析。
Indian J Ophthalmol. 2022 Aug;70(8):2906-2910. doi: 10.4103/ijo.IJO_2947_21.
2
RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis.RKI-1447，一种Rho激酶抑制剂，可导致眼压降低、肌动蛋白应激纤维破坏以及吞噬作用增强。
Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):101-109. doi: 10.1007/s00417-018-4175-6. Epub 2018 Nov 19.
3
Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.奈他地尔滴眼液的概况及其在开角型青光眼治疗中的潜力：迄今的证据
Clin Ophthalmol. 2018 Oct 4;12:1939-1944. doi: 10.2147/OPTH.S154001. eCollection 2018.
Zotero 插件